SOHO 2023 | The impact of induction therapy on post-transplant outcomes in AML
Nicholas Short
• 6 Sep 2023
Frontline therapy for older adult patients with acute myeloid leukemia (AML) is typically intensive chemotherapy, or a lower intensity regimen of azacitidine and venetoclax. Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of an analysis investigating the impact of the type of induction therapy on the outcomes of patients with AML after allogeneic stem cell transplantation (alloSCT). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
